Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04295850 · ClinicalTrials.gov registry record

Antenatal Platelet Response On Aspirin and Correlation With HDP (Hypertensive Disorders of Pregnancy)

A clinical trial of Preeclampsia, sponsored by Thomas Jefferson University.

Completed
Registry status
130
Enrollment target
1
Study location

NCT04295850 is a study of Preeclampsia that has completed, run by Thomas Jefferson University. The registered enrollment target is 130 participants, below the 1,279-participant average among 39 other Preeclampsia trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04295850, a study of Preeclampsia, has completed, sponsored by Thomas Jefferson University.

COMPLETED
Registry status
130 participants
Enrollment target
1
Study location

Study Summary

This proposal has three aims to characterize the relationship between aspirin therapy, platelet function response, and prevention of hypertensive disorders of pregnancy (HDP) through a prospective, cohort study using pharmacokinetics, pharmacodynamics, pharmacogenomics and bioinformatics. The results of this proposal will provide necessary data for prospective study on individualized aspirin dose adjustment for prevention of HDP.

Conditions Studied

Interventions

  • DRUG Aspirin 81 mg

Study Locations (1)

Pennsylvania

  • Thomas Jefferson University Hospital - Philadelphia

Trial Details

FieldValue
Enrollment Target 130 participants
Start Date 2020-08-21
Est. Completion 2023-06-30

Sponsor

Thomas Jefferson University

292 total trials

What the Registry Record Tells You About NCT04295850

The ClinicalTrials.gov registry entry for NCT04295850 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,279-participant average among 39 other Preeclampsia trials with a reported enrollment target (90% lower). The listed sponsor is Thomas Jefferson University, which has 292 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Preeclampsia appearing as the primary indexed condition, and to 1 intervention - of which Aspirin 81 mg is the first listed.

NCT04295850 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT04295850 about?

NCT04295850 is a clinical study titled "Antenatal Platelet Response On Aspirin and Correlation With HDP (Hypertensive Disorders of Pregnancy)". This proposal has three aims to characterize the relationship between aspirin therapy, platelet function response, and prevention of hypertensive disorders of pregnancy (HDP) through a prospective, cohort study using pharmacokinetics, pharmacodynamics, pharmacogenomics and bioinformatics. The result...

What is the current status of trial NCT04295850?

This trial is currently completed. The enrollment target is 130 participants. The study started on 2020-08-21. Estimated completion is 2023-06-30.

What conditions does trial NCT04295850 study?

This clinical trial studies the following conditions: Preeclampsia.

What interventions are being tested in trial NCT04295850?

The interventions under investigation include: Aspirin 81 mg (DRUG).

Who is sponsoring clinical trial NCT04295850?

This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04295850 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Preeclampsia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.